Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 52, Status: Authorised

Human medicines European public assessment report (EPAR): Striascan, ioflupane (123l), Date of authorisation: 25/06/2019, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of authorisation: 09/01/2026, Revision: 1, Status: Authorised

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2026

Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Status: Opinion

Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Status: Opinion

Human medicines European public assessment report (EPAR): Palbociclib Viatris, palbociclib, Status: Opinion

Human medicines European public assessment report (EPAR): Redemplo, plozasiran, Status: Opinion

Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Status: Opinion

Human medicines European public assessment report (EPAR): Viokat, diazoxide choline, Status: Application withdrawn